Functional-metabolic imaging of neuroblastoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 1, 2013, Pages 6-20

  Sharp, S E ^a   Parisi, M T ^b   Gelfand, M J ^a   Yanik, G A ^c   Shulkin, B L ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

3 Iodobenzylguanidine; Neuroblastoma; Positron emission tomography and computed tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

BONE SCINTISCANNING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME;

3-IODOBENZYLGUANIDINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DIAGNOSTIC IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; NEUROBLASTOMA; PROGNOSIS; RADIONUCLIDE IMAGING; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84876547320     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-85.
2. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002;22:911-34.
3. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21(3):181-9. (Pubitemid 30306028)
4. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298-303.
5. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243-57.
6. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
7. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47:561-71.
8. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65. (Pubitemid 46190236)
9. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466-73. (Pubitemid 46190237)
10. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005;23:6474-80. (Pubitemid 46190238)
11. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007 Jun 23;369:2106-20. (Pubitemid 46935947)
12. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
13. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65-86.
14. Maris JM. Recent Advances in Neuroblastoma. N Engl J Med 2010;362:2202-11.
15. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73. (Pubitemid 29480654)
16. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13.
17. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-64. (Pubitemid 28175737)
18. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313-23.
19. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P et al. Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. J Clin Oncol 201220;30:1842-8.
20. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008;26:1504-10.
21. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26:791-6. (Pubitemid 40019177)
22. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C et a. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:477-86. (Pubitemid 30078529)
23. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172-88. (Pubitemid 47611663)
24. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405. (Pubitemid 32642193)
25. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
26. Stark DD, Moss AA, Brasch RC, deLorimier AA, Albin AR, London DA et al. Neuroblastoma: diagnostic imaging and staging. Radiology 1983;148:101-5. (Pubitemid 13107790)
27. Stark DD, Brasch RC, Moss AA, deLorimier AA, Albin AR, London DA et al. Recurrent neuroblastoma: the role of CT and alternative imaging tests. Radiology 1983;148:107-12. (Pubitemid 13107791)
28. Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D et al. Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology 2002;223:168-75. (Pubitemid 34258205)
29. Hugosson C, Nyman R, Jorulf H, McDonald P, Rifai A, Kofide A et al. Imaging of abdominal neuroblastoma in children. Acta Radiol 1999;40:534-42. (Pubitemid 129567267)
30. Sofka CM, Semelka RC, Kelekis NL, Worawattanakul S, Chung CJ, Gold S et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging 1999;17:193-8. (Pubitemid 29053177)
31. Leung A, Shapiro B, Hattner R, Kim E, de KJ, Ghazzar N et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352-7. (Pubitemid 27386188)
32. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217-23. (Pubitemid 29500578)
33. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 1987;15:170-7. (Pubitemid 18025972)
34. Smets LA, Loesberg C,ssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989 1;49:2941-4.
35. Smets LA,ssen M, Metwally E, Loesberg C. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990 15;39:1959-64.
36. Treuner J, Feine U, Niethammer D, Muller-Schaumburg W, Meinke J, Eibach E, et al.. Scintigraphic imaging of neuroblastoma with [131-I] iodobenzylguanidine. Lancet 1984 11;1:333-4.
37. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum WK. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 1984;25:773-5. (Pubitemid 14087142)
38. Geatti O, Shapiro B, Sisson JC, Hutchinson RJ, Mallette S, Eyre P et a. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985;26:736-42. (Pubitemid 16005495)
39. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof DA, Maffioli L et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-46.
40. Wood DE, Gilday DL, Kellan J. Stable iodine requirements for thyroid gland blockage of iodinated radiopharmaceuticals. J Can Assoc Radiol 1974;25:295-6.
41. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45-B50.
42. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V et al. Criteria for evaluation of disease extent by (123)I- metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010 27;102.1319-26.
43. Gelfand MJ, Parisi MT, Treves ST. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 2011;52:318-22.
44. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009;52:784-90.
45. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994;35:1753-7. (Pubitemid 24346793)
46. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-8. (Pubitemid 26321623)
47. Suc As, Lumbroso J, Rubie H, Hattchouel JM, Boneu Ae, Rodary C, et al. Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805-11.
48. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bonerow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-65. (Pubitemid 28108728)
49. Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999;21:13-8. (Pubitemid 29131988)
50. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-90. (Pubitemid 351571524)
51. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 2011;36:1-7.
52. Snay ER, Treves ST, Fahey FH. Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol 2011;39:100-4.
53. Englaro EE, Gelfand MJ, Harris RE, Smith HS. I-131 MIBG imaging after bonerow transplantation for neuroblastoma. Radiology 1992;182:515-20.
54. Tanabe M, Ohnuma N, Iwai J, Yoshida H, Takahashi H, Maie M et al. Bonerow metastasis of neuroblastoma analyzed by MRI and its influence on prognosis. Med Pediatr Oncol 1995 May;24:292-9.
55. Lebtahi N, Gudinchet F, Nenadov-Beck M, Beck D, Bischof DA. Evaluating bonerow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med 1997;38:1389-92. (Pubitemid 27386197)
56. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
57. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343-9.
58. Acharya J, Chang PT, Gerard P. Abnormal MIBG uptake in a neuroblastoma patient with right upper lobe atelectasis. Pediatr Radiol 2012;42:1259-62.
59. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041-6.
60. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552-8.
61. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J et al. A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256-61.
62. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000;34:237-41. (Pubitemid 30176598)
63. Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamine metabolites, mIBG scan, and bonerow cytology as responsekers in stage 4 neuroblastoma. Med Pediatr Oncol 2001;36:220-3.
64. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003 1;21:2486-91.
65. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74. (Pubitemid 44656106)
66. Lewington V, Bar-Sever Z, Machin D. Development of a new, semiquantitative I-123 mIBG reporting method in high risk neuroblastoma. Eur J Nucl Med Mol Imaging 2009;36:334.
67. Paltiel HJ, Gelfand MJ, Elgazzar AH, Washburn LC, Harris RE, Masters PR et al. Neural crest tumors: I-123 MIBG imaging in children. Radiology 1994;190:117-21.
68. Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-10. (Pubitemid 24151215)
69. Schindler T, Yu C, Rossleigh M, Pereira J, Cohn R. False-positive MIBG uptake in pneumonia in a patient with stage IV neuroblastoma. Clin Nucl Med 2010;35:743-5.
70. Okuyama C, Sakane N, Yoshida T, Shima K, Kurosawa H, Kumamoto K et al. (123)1- or (125)I-metaiodobenzylguanidine visualization of brown adipose tissue. J Nucl Med 2002;43:1234-40. (Pubitemid 34988772)
71. Okuyama C, Ushijima Y, Kubota T, Yoshida T, Nakai T, Kobayashi K et al. 123I-Metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue. J Nucl Med 2003;44:1421-5. (Pubitemid 39663354)
72. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S et al. Integrated imaging using MRI and 123I metaiodobenzyl-guanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24. (Pubitemid 37151800)
73. Melzer HI, Coppenrath E, Schmid I, Albert MH, von SD, Tudball C et al. I-MIBG scintigraphy/SPECT versus F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011;38:1648-58.
74. Jacobsson H, Hellstrom PM, Kogner P, Larsson SA. Different concentrations of I-123 MIBG and In-111 pentetreotide in the two main liver lobes in children: persisting regional functional differences after birth? Clin Nucl Med 2007;32:24-8. (Pubitemid 46360588)
75. Heyman S, Evans AE, D'Angio GJ. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 1988;16:337-40. (Pubitemid 18265424)
76. Schmiegelow K, Simes MA, Agertoft L, Berglund G, Storm-Mathisen I, Andreassen M et al. Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations. Med Pediatr Oncol 1989;17:127-30.
77. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De BB. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35:153-5.
78. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-6. (Pubitemid 46594137)
79. Hickeson MP, Charron M,is JM, Brophy P, Kang TI, Zhuang H et al. Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004;42:268-74. (Pubitemid 38235078)
80. Parisi MT, Matthay KK, Huberty JP, Hattner RS. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology 1992;184:463-7.
81. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
82. Papathanasiou ND, Gaze MN, Sullivan K, Aldridge M, Waddington W, Almuhaideb A et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 2011;52:519-25.
83. Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2008;51:828-31.
84. Mc DH, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2009;52:552.
85. Goodin GS, Shulkin BL, Kaufman RA, McCarville MB. PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease. AJR Am J Roentgenol 2006;187:1124-8. (Pubitemid 44453972)
86. Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics 2009;29:1467-86.
87. Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006;47:1635-42. (Pubitemid 47545029)
88. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996;37:16-21. (Pubitemid 26125958)
89. Shulkin BL, Wieland DM, Castle VP. Carbon-11 epinephrine PET imaging of neuroblastoma. J Nucl Med 1999;40S:129.
90. Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med 2012;37:e73-e78.
91. Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012;39:57-71.
92. Valentiner U, Haane C, Peldschus K, Gustke H, Brenner W, Wilke F et al. [18F]FDG and [18F]RT PET-CT and MR imaging of human neuroblastomas in a SCID mouse xenograft model. Anticancer Res 2008;28:2561-8.
93. Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH et al. Characterization of Neuroblastic Tumors Using 18F-FDOPA PET. J Nucl Med 2013;54:42-9.
94. Krieger-Hinck N, Gustke H, Valentiner U, Mikecz P, Buchert R, Mester J et al. Visualisation of neuroblastoma growth in a Scid mouse model using [18F]FDG and [18F]FLT-PET. Anticancer Res 2006;26:3467-72. (Pubitemid 44701524)
95. Kroiss A, Putzer D, Uprimny C,ristoforo C, Gabriel M, Santner W et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011;38:865-73.
96. Vaidyanathan G, Zhao XG, Strickland DK, Zalutsky MR. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med 1997;38:330-4. (Pubitemid 27061621)
97. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644-50.
98. Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[18F]fluoro-3-iodobenzyl) guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem 1994;37:3655-62. (Pubitemid 24334620)